International Trachoma Initiative (ITI)
The International Trachoma Initiative (ITI) was founded in 1998 in response to the World Health Organization’s (WHO) call to eliminate blinding trachoma by 2020 (GET2020). ITI is dedicated to the elimination of blinding trachoma by collaborating with governmental and nongovernmental agencies at the local, national and international levels.
ITI advocates for the implementation of the WHO-recommended SAFE strategy for trachoma control (Surgery; Antibiotics—including donated Zithromax®; Facial cleanliness; and Environmental improvement).
Implementation of all components of the SAFE strategy relies on multiple partnerships in various sectors such as water, sanitation and education that are essential to achieving our shared goal of elimination.
Since 1998, ITI has managed the donation of Zithromax® from Pfizer Inc. as a part of the "A" component of the SAFE strategy. To date, Pfizer has donated more than 225 million Zithromax® treatments through ITI. This medicine has reached millions of people in 19 countries. ITI plans to be active in more than 42 countries by 2015.
The U.S. Fund for UNICEF works with ITI and Pfizer to support the effort to eliminate blinding trachoma by raising awareness of the disease and facilitating the delivery of Zithromax® donated by Pfizer to the U.S. Fund for UNICEF.